CSL Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMXHF research report →
About the company
CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company's activities are organized into two primary divisions: CSL Behring and Seqirus.
- CEO
- Gordon Naylor DipCompSc
- IPO
- 2005
- Employees
- 32,698
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $39.84B
- P/E
- 28.38
- P/S
- 2.58
- P/B
- 2.19
- EV/EBITDA
- 10.09
- Div Yield
- 3.50%
- Gross Margin
- 48.64%
- Op Margin
- 25.72%
- Net Margin
- 9.17%
- ROE
- 7.56%
- ROIC
- 10.37%
- Revenue
- $15.43B · 4.26%
- Net Income
- $3.00B · 13.63%
- EPS
- $6.20 · 13.35%
- Op Income
- $2.96B
- FCF YoY
- 68.92%
- 52W High
- $184.09
- 52W Low
- $63.84
- 50D MA
- $77.27
- 200D MA
- $106.09
- Beta
- 0.09
- Avg Volume
- 2.35K
Get TickerSpark's AI analysis on CMXHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CMXHF coverage
Recent articles, reports, and earnings notes.
No research on CMXHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMXHF report →Similar companies
Peers in the same neighborhood.